Source: International Congress 2017 – Infection and exacerbation science
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
E. Tsitoura (Heraklion, Crete, Greece). Activin-A levels in sputum and serum of COPD, asthma and ACOS patients during acute exacerbation and at baseline. 997

Member's Comments

No comment yet.

Related content which might interest you: Change of induced sputum TNF-a and sTNF-R55,75 levels in patients with acute exacerbations of COPD Source: Annual Congress 2007 - Respiratory pathophysiology Year: 2007 Sputum VEGF level increases with treatment of COPD acute exacerbation Source: Annual Congress 2012 - COPD monitoring in stable disease and during exacerbation Year: 2012 Il-6 levels in sera and induced sputum of COPD patients during exacerbations and stable period Source: Eur Respir J 2005; 26: Suppl. 49, 284s Year: 2005 Serum SP-A and SP-D levels in patients admitted to the hospital with acute COPD exacerbation Source: International Congress 2016 – Inflammatory biomarkers in airway diseases Year: 2016 Relationship between CRP levels and the severity of COPD acute exacerbations among group D COPD patients. Source: Virtual Congress 2020 – COPD phenotypes Year: 2020 Serum periostin in patients hospitalized for COPD exacerbations Source: International Congress 2015 – Exploring mechanisms in obstructive airway diseases Year: 2015 Increased serum endotoxin levels as biomarker in acute exacerbations of COPD. Source: International Congress 2018 – Biomarkers of COPD Year: 2018 Serum hyaluronidase-1 is increased in COPD exacerbations and is associated with COPD severity and outcomes Source: International Congress 2018 – Disease exacerbations from a molecular point of view Year: 2018 Vip in the serum of asthmatic patients and in COPD patients in stable state and during exacerbation Source: Eur Respir J 2007; 30: Suppl. 51, 403s Year: 2007 Serum interleukin-6 levels correlate with malnutrition in patients with acute exacerbation of COPD Source: Annual Congress 2009 - Organisation of care for individuals with chronic respiratory disease Year: 2009 A study of the level of interleukin-32 in induced sputum and plasma of patients with chronic obstructive pulmonary disease and asthma Source: Annual Congress 2010 - Novel mechanisms in COPD Year: 2010 MMP-9 expression and activity is incresed in the BAL of patients with acute exacerbation of COPD Source: Annual Congress 2012 - Inflammatory mechanisms in COPD Year: 2012 Time course of sputum and serum interleukin-6 during COPD exacerbations Source: Eur Respir J 2005; 26: Suppl. 49, 464s Year: 2005 Cytokines levels of blood and sputum in COPD exacerbation Source: Annual Congress 2010 - Colonisation and infection in COPD Year: 2010 Altered expression of glycosaminoglycans in the BAL of COPD patients with acute exacerbation Source: Annual Congress 2013 –Translational studies in chronic lung diseases: from bedside to bench Year: 2013 Serum magnesium levels in acute exacerbation of COPD Source: Annual Congress 2007 - Exacerbations of COPD Year: 2007 The influence of the COPD exacerbation treatment on the MMP-9 concentration in serum, induced sputum and BAL Source: Eur Respir J 2005; 26: Suppl. 49, 298s Year: 2005 Sputum purulence-guided antibiotic use in hospitalised patients with exacerbations of COPD Source: Eur Respir J 2012; 40: 1344-1353 Year: 2012 Changes of IL-6 level in bronchoalveolar fluid in patients with acute exacerbation of COPD before and after the treatment with tiotropium bromide, and its significance Source: Annual Congress 2013 –COPD: new markers of diseases Year: 2013 The assesment of serum TNFα levels in COPD acute exacerbation and the effects of inhaler steroids on clinical and inflammatory determinants Source: Eur Respir J 2002; 20: Suppl. 38, 312s Year: 2002